ADIPOQ and obesity disorder: Low concentrations of adiponectin are associated with an increased risk of obesity [52], whereas increased adiponectin favors fat metabolism, which may be related to the reduction in triglycerides, total HDL, and LDL-cholesterol observed after genistein administration (54 mg/day) for six or twelve months [43,51].